| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,189 | 3,286 | 3,333 | 3,653 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,227 | 2,383 | 2,401 | 2,724 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 962 | 903 | 933 | 930 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 106 | 187 | 231 | 219 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 |
Mankind Pharma
Mankind Pharma
2,416.10
-31.90
(-1.30%)
Market Cap
99,726.58 Cr
EPS
49.28
PE Ratio
53.47
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
3,054.80
52 Week Low
2,115.10
PB Ratio
7.05
Debt to Equity
0.37
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Mankind Pharma executed a block trade worth Rs. 51.37 crores on the National Stock Exchange. The transaction involved approximately 200,287 shares at a price of Rs. 2,564.60 per share.
Mankind Pharma plans to eliminate its debt by FY28, with Managing Director Rajeev Juneja stating the company will be almost debt-free by FY27. The pharmaceutical company currently carries net debt of ₹5,200 crore and follows a conservative debt approach. Mankind expects to be among the first wave of GLP-1 launches in India, targeting the obesity treatment segment, which Juneja believes will see significant growth over the next 5-10 years. The company's consumer brand Gas-o-Fast is performing strongly, and it recently launched Nemulid after acquiring the brand from Panacea Biotech. Mankind has established a specialized OTC division to strengthen its consumer health business, which currently contributes 8-9% of revenue and is expected to grow in the high teens. Exports represent 13-14% of business including BSV, with the US contributing just 1%, though the company expects double-digit export growth ahead.
Mankind Pharma Ltd. recorded a block trade worth Rs. 50.95 crores on the NSE. The transaction involved approximately 202,622 shares at a price of Rs. 2,514.70 per share.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,635.50 | #1 3,92,411.23 | 34.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 55.14 | |
5,840.00 | 1,55,033.65 | 67.54 | 9,712.00 | 18.67 | 2,191 | 26.74 | 30.76 | |
1,507.60 | 1,21,777.00 | 22.70 | 28,409.50 | 7.12 | 5,291 | 9.88 | 42.86 | |
3,490.00 | 1,18,117.46 | 58.89 | 11,539.40 | 6.99 | 1,911 | 19.91 | 47.37 | |
1,243.80 | 1,03,809.26 | #1 18.34 | 33,741.20 | 16.73 | 5,725 | 1.26 | 41.85 | |
2,416.10 | #6 99,726.58 | #8 53.47 | #7 12,744.20 | #1 20.90 | #8 2,007 | #9 -18.14 | 35.51 | |
985.10 | 99,124.11 | 21.34 | 23,511.00 | 18.55 | 4,615 | 2.60 | 43.75 | |
1,939.10 | 88,569.27 | 24.35 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 51.60 | |
5,405.00 | 64,624.88 | 28.57 | 13,458.30 | 3.70 | 2,216 | 21.39 | 55.81 | |
30,215.00 | 64,204.77 | 43.81 | 6,684.70 | 9.64 | 1,414 | 11.55 | 36.82 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,148 | 9,715 | 11,963 | 27,760 |
| Fixed Assets | 3,588 | 4,251 | 4,545 | 19,005 |
| Current Assets | 4,407 | 4,328 | 6,568 | 6,988 |
| Capital Work in Progress | 702 | 550 | 282 | 826 |
| Investments | 1,110 | 1,346 | 2,568 | 2,042 |
| Other Assets | 3,749 | 3,568 | 4,568 | 5,887 |
| Total Liabilities | 9,148 | 9,715 | 11,963 | 27,760 |
| Current Liabilities | 2,624 | 1,863 | 2,120 | 5,664 |
| Non Current Liabilities | 208 | 229 | 268 | 7,528 |
| Total Equity | 6,316 | 7,623 | 9,576 | 14,568 |
| Reserve & Surplus | 6,115 | 7,395 | 9,323 | 14,291 |
| Share Capital | 40 | 40 | 40 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,506.95 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,430.05 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.00 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,386.35 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.00 | 2,541.90 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
1 day ago
1 day agoClosure of Trading Window10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Intimation Of Receipt Of Approval For ReclassificationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Intimation Regarding ESG RatingAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Intimation For Submission Of Application For ReclassificationAug 03, 2025
Aug 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Aug 01, 2025Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RestructuringJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 31, 2025
Jul 31, 2025Intimation Of Record DateJul 31, 2025
Jul 31, 2025Corporate Action-Board approves DividendJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Un-Audited Financial Results For The Quarter Ended On June 30 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 24, 2025
Jul 24, 2025Intimation Of Receipt Of Request For ReclassificationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Jul 18, 2025Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Jul 17, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 15, 2025
Jul 15, 2025Reg. 34 (1) Annual Report.Jul 15, 2025
Jul 15, 2025Notice Of 34Th Annual General Meeting Of Mankind Pharma LimitedJul 15, 2025
Jul 15, 2025Closure of Trading WindowJul 14, 2025
Jul 14, 2025Corporate Action-Board to consider DividendJul 14, 2025
Jul 14, 2025Board Meeting Intimation for Unaudited Quarterly Financial Results & Interim DividendJul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Jul 04, 2025Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The CompanyJul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 10, 2025
Jun 10, 2025Intimation Under Regulations 30 & 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Environmental Social And
Governance (ESG) RatingJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
May 27, 2025Technical Indicators
RSI(14)
Neutral 37.12
ATR(14)
Volatile 56.53
STOCH(9,6)
Oversold 11.17
STOCH RSI(14)
Oversold 3.36
MACD(12,26)
Bearish -18.88
ADX(14)
Weak Trend 19.03
UO(9)
Bearish 42.32
ROC(12)
Downtrend And Accelerating -4.74
WillR(14)
Oversold -82.60
Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
Edelweiss Mid Cap Direct Plan-Growth 
Invesco India Multicap Fund Direct-Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
Mirae Asset Aggressive Hybrid Fund Direct-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
DSP Arbitrage Fund Direct - Growth 
Nippon India Arbitrage Fund Direct-Growth 
Canara Robeco Large and Mid Cap Fund Direct-Growth 
Sundaram Aggressive Hybrid Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years,
-3 days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
